Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration

References

• Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16:2927 - 31; http://dx.doi.org/10.1158/1078-0432.CCR-09-2329; PMID: 20484021
   PubMed Web of Science ®Google Scholar
• Zagzag D, Krishnamachary B, Yee H, Okuyama H, Chiriboga L, Ali MA, et al. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 2005; 65:6178 - 88; http://dx.doi.org/10.1158/0008-5472.CAN-04-4406; PMID: 16024619
   PubMed Web of Science ®Google Scholar
• Struckmann K, Mertz K, Steu S, Storz M, Staller P, Krek W, et al. pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J Pathol 2008; 214:464 - 71; http://dx.doi.org/10.1002/path.2310; PMID: 18189328
   PubMed Web of Science ®Google Scholar
• do Carmo A, Patricio I, Cruz MT, Carvalheiro H, Oliveira CR, Lopes MC. CXCL12/CXCR4 promotes motility and proliferation of glioma cells. Cancer Biol Ther 2010; 9:56 - 65; http://dx.doi.org/10.4161/cbt.9.1.10342; PMID: 19923906
   PubMed Web of Science ®Google Scholar
• Carlisle AJ, Lyttle CA, Carlisle RY, Maris JM. CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation. Mol Cancer 2009; 8:126; http://dx.doi.org/10.1186/1476-4598-8-126; PMID: 20028517
   PubMed Web of Science ®Google Scholar
• Ottaiano A, Franco R, Aiello Talamanca A, Liguori G, Tatangelo F, Delrio P, et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 2006; 12:2795 - 803; http://dx.doi.org/10.1158/1078-0432.CCR-05-2142; PMID: 16675573
   PubMed Web of Science ®Google Scholar
• Engl T, Relja B, Marian D, Blumenberg C, Müller I, Beecken WD, et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 2006; 8:290 - 301; http://dx.doi.org/10.1593/neo.05694; PMID: 16756721
   PubMed Web of Science ®Google Scholar
• Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005; 11:1835 - 41; http://dx.doi.org/10.1158/1078-0432.CCR-04-1887; PMID: 15756007
   PubMed Web of Science ®Google Scholar
• Marchesi F, Monti P, Leone BE, Zerbi A, Vecchi A, Piemonti L, et al. Increased survival, proliferation and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004; 64:8420 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-04-1343; PMID: 15548713
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003; 167:1676 - 86; http://dx.doi.org/10.1164/rccm.200301-071OC; PMID: 12626353
   PubMed Web of Science ®Google Scholar
• Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002; 62:5930 - 8; PMID: 12384559
   PubMed Web of Science ®Google Scholar
• Schrader AJ, Lechner O, Templin M, Dittmar KE, Machtens S, Mengel M, et al. CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer 2002; 86:1250 - 6; http://dx.doi.org/10.1038/sj.bjc.6600221; PMID: 11953881
   PubMed Web of Science ®Google Scholar
• Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, Reckamp K, et al. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 2006; 5:56; http://dx.doi.org/10.1186/1476-4598-5-56; PMID: 17083723
   PubMed Web of Science ®Google Scholar
• Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003; 425:307 - 11; http://dx.doi.org/10.1038/nature01874; PMID: 13679920
   PubMed Web of Science ®Google Scholar
• Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009; 107:600 - 8; http://dx.doi.org/10.1002/jcb.22185; PMID: 19459166
   PubMed Web of Science ®Google Scholar
• Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007; 16:1111 - 20; http://dx.doi.org/10.1517/13543784.16.7.1111; PMID: 17594194
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001; 98:2865 - 8; http://dx.doi.org/10.1182/blood.V98.9.2865; PMID: 11675364
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Sackett DL, Bates SE. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J 2007; 13:30 - 9; http://dx.doi.org/10.1097/PPO.0b013e31803c73cc; PMID: 17464244
   PubMed Web of Science ®Google Scholar
• Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J Urol 2008; 180:1131 - 6; http://dx.doi.org/10.1016/j.juro.2008.04.136; PMID: 18639283
   PubMed Web of Science ®Google Scholar
• Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8:718 - 28; PMID: 11895901
   PubMed Web of Science ®Google Scholar
• Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006; 5:57 - 60; http://dx.doi.org/10.3816/CGC.2006.n.018; PMID: 16859580
   PubMed Web of Science ®Google Scholar
• Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, et al. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med 2009; 13:8B 2376 - 85; http://dx.doi.org/10.1111/j.1582-4934.2008.00436.x; PMID: 18657224
   PubMed Web of Science ®Google Scholar
• Crazzolara R, Jöhrer K, Johnstone RW, Greil R, Kofler R, Meister B, et al. Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br J Haematol 2002; 119:965 - 9; http://dx.doi.org/10.1046/j.1365-2141.2002.03955.x; PMID: 12472574
   PubMed Web of Science ®Google Scholar
• Stamatopoulos B, Meuleman N, De Bruyn C, Delforge A, Bron D, Lagneaux L. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Haematologica 2010; 95:1136 - 43; http://dx.doi.org/10.3324/haematol.2009.013847; PMID: 20145270
   PubMed Web of Science ®Google Scholar
• Gul H, Marquez-Curtis LA, Jahroudi N, Lo J, Turner AR, Janowska-Wieczorek A. Valproic acid increases CXCR4 expression in hematopoietic stem/progenitor cells by chromatin remodeling. Stem Cells Dev 2009; 18:831 - 8; http://dx.doi.org/10.1089/scd.2008.0235; PMID: 18847317
   PubMed Web of Science ®Google Scholar
• Gul H, Marquez-Curtis LA, Jahroudi N, Larratt LM, Janowska-Wieczorek A. Valproic acid exerts differential effects on CXCR4 expression in leukemic cells. Leuk Res 2010; 34:235 - 42; http://dx.doi.org/10.1016/j.leukres.2009.05.014; PMID: 19539992
   PubMed Web of Science ®Google Scholar
• Mori T, Kim J, Yamano T, Takeuchi H, Huang S, Umetani N, et al. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 2005; 65:1800 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-04-3531; PMID: 15753377
   PubMed Web of Science ®Google Scholar
• Kim SW, Kim HY, Song IC, Jin SA, Lee HJ, Yun HJ, et al. Cytoplasmic trapping of CXCR4 in hepatocellular carcinoma cell lines. Cancer Res Treat 2008; 40:53 - 61; http://dx.doi.org/10.4143/crt.2008.40.2.53; PMID: 19688049
   PubMedGoogle Scholar
• Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res 2006; 12:1547 - 55; http://dx.doi.org/10.1158/1078-0432.CCR-05-1423; PMID: 16533780
   PubMed Web of Science ®Google Scholar
• Huang YC, Hsiao YC, Chen YJ, Wei YY, Lai TH, Tang CH. Stromal cell-derived factor-1 enhances motility and integrin up-regulation through CXCR4, ERK and NF-kappaB-dependent pathway in human lung cancer cells. Biochem Pharmacol 2007; 74:1702 - 12; http://dx.doi.org/10.1016/j.bcp.2007.08.025; PMID: 17904532
   PubMed Web of Science ®Google Scholar
• Shen X, Artinyan A, Jackson D, Thomas RM, Lowy AM, Kim J. Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways. Pancreas 2010; 39:81 - 7; http://dx.doi.org/10.1097/MPA.0b013e3181bb2ab7; PMID: 19820417
   PubMed Web of Science ®Google Scholar
• Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta 2007; 1768:952 - 63; http://dx.doi.org/10.1016/j.bbamem.2006.11.002; PMID: 17169327
   PubMed Web of Science ®Google Scholar
• Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6:587 - 95; http://dx.doi.org/10.1038/nrclinonc.2009.129; PMID: 19787002
   PubMed Web of Science ®Google Scholar
• Ahr B, Denizot M, Robert-Hebmann V, Brelot A, Biard-Piechaczyk M. Identification of the cytoplasmic domains of CXCR4 involved in Jak2 and STAT3 phosphorylation. J Biol Chem 2005; 280:6692 - 700; http://dx.doi.org/10.1074/jbc.M408481200; PMID: 15615703
   PubMed Web of Science ®Google Scholar
• Pfeiffer M, Hartmann TN, Leick M, Catusse J, Schmitt-Graeff A, Burger M. Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer. Br J Cancer 2009; 100:1949 - 56; http://dx.doi.org/10.1038/sj.bjc.6605068; PMID: 19455144
   PubMed Web of Science ®Google Scholar
• Fernandis AZ, Prasad A, Band H, Klösel R, Ganju RK. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004; 23:157 - 67; http://dx.doi.org/10.1038/sj.onc.1206910; PMID: 14712221
   PubMed Web of Science ®Google Scholar
• Lin KT, Yeh SH, Chen DS, Chen PJ, Jou YS. Epigenetic activation of alpha4, beta2 and beta6 integrins involved in cell migration in trichostatin A-treated Hep3B cells. J Biomed Sci 2005; 12:803 - 13; http://dx.doi.org/10.1007/s11373-005-9005-2; PMID: 16132114
   PubMed Web of Science ®Google Scholar
• Wu LP, Wang X, Li L, Zhao Y, Lu S, Yu Y, et al. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol Cell Biol 2008; 28:3219 - 35; http://dx.doi.org/10.1128/MCB.01516-07; PMID: 18332107
   PubMed Web of Science ®Google Scholar
• To KK, Polgar O, Huff LM, Morisaki K, Bates SE. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res 2008; 6:151 - 64; http://dx.doi.org/10.1158/1541-7786.MCR-07-0175; PMID: 18234970
   PubMed Web of Science ®Google Scholar
• McGarvey KM, Van Neste L, Cope L, Ohm JE, Herman JG, Van Criekinge W, et al. Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res 2008; 68:5753 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-08-0700; PMID: 18632628
   PubMed Web of Science ®Google Scholar
• Park H, Im JY, Kim J, Choi WS, Kim HS. Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells. Int J Mol Med 2008; 21:325 - 33; PMID: 18288380
   PubMed Web of Science ®Google Scholar
• Chen J, Rusnak M, Lombroso PJ, Sidhu A. Dopamine promotes striatal neuronal apoptotic death via ERK signaling cascades. Eur J Neurosci 2009; 29:287 - 306; http://dx.doi.org/10.1111/j.1460-9568.2008.06590.x; PMID: 19200235
   PubMed Web of Science ®Google Scholar
• Pettersson F, Couture MC, Hanna N, Miller WH. Enhanced retinoid-induced apoptosis of MDA-MB-231 breast cancer cells by PKC inhibitors involves activation of ERK. Oncogene 2004; 23:7053 - 66; http://dx.doi.org/10.1038/sj.onc.1207956; PMID: 15273718
   PubMed Web of Science ®Google Scholar
• Zhang XF, Wang JF, Matczak E, Proper JA, Groopman JE. Janus kinase 2 is involved in stromal cell-derived factor-1alpha-induced tyrosine phosphorylation of focal adhesion proteins and migration of hematopoietic progenitor cells. Blood 2001; 97:3342 - 8; http://dx.doi.org/10.1182/blood.V97.11.3342; PMID: 11369622
   PubMed Web of Science ®Google Scholar
• Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, et al. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 2004; 65:520 - 7; http://dx.doi.org/10.1124/mol.65.3.520; PMID: 14978230
   PubMed Web of Science ®Google Scholar
• Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 2006; 281:5612 - 22; http://dx.doi.org/10.1074/jbc.M507213200; PMID: 16377638
   PubMed Web of Science ®Google Scholar
• Liu LT, Chang HC, Chiang LC, Hung WC. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 2003; 63:3069 - 72; PMID: 12810630
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Motoki T, Kubota S, Takigawa M, Tsubouchi H, Gohda E. Inhibition of tumor-stromal interaction through HGF/Met signaling by valproic acid. Biochem Biophys Res Commun 2008; 366:110 - 6; http://dx.doi.org/10.1016/j.bbrc.2007.11.089; PMID: 18053801
   PubMed Web of Science ®Google Scholar